<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498992</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000553120</org_study_id>
    <secondary_id>IMH-REG-ING-100</secondary_id>
    <secondary_id>MPMM-IMH-REG-ING-100</secondary_id>
    <nct_id>NCT00498992</nct_id>
  </id_info>
  <brief_title>Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer</brief_title>
  <official_title>Regenecare® in the Treatment of Skin Rash Associated With Cetuximab (Erbitux®) or Other EGFR Treated Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ingalls Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Regenecare® wound gel may help relieve pain and itching in patients who develop an&#xD;
      acne-like rash while undergoing treatment with cetuximab or another epidermal growth factor&#xD;
      receptor inhibitor for cancer.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well Regenecare® wound gel works in treating&#xD;
      rash in patients receiving cetuximab or another epidermal growth factor receptor inhibitor&#xD;
      therapy for cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of Regenecare® wound gel in alleviating pain and itching in&#xD;
           patients who develop an acneiform rash while undergoing treatment with cetuximab or&#xD;
           other EGFR inhibitor therapy for cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the efficacy of this drug in reducing the severity of rash in these patients.&#xD;
&#xD;
        -  Determine the efficacy of this drug in reducing the redness and appearance of the rash&#xD;
           in these patients.&#xD;
&#xD;
        -  Determine the tolerability of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a prospective study.&#xD;
&#xD;
        -  Observation: Patients undergo evaluation by full-face photography prior to development&#xD;
           of skin rash (baseline). While undergoing concurrent cancer therapy, patients&#xD;
           self-monitor for the appearance of an acneiform rash. Upon initial onset of rash,&#xD;
           patients proceed to treatment.&#xD;
&#xD;
        -  Treatment: Patients apply topical Regenecare® wound gel to the face ≥ 4 times daily.&#xD;
           Treatment continues for 4 weeks in the absence of unacceptable toxicity.&#xD;
&#xD;
      Patients are evaluated weekly by facial examination, full-face photography, and patient&#xD;
      satisfaction questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Regenecare® wound gel, in terms of alleviating pain and itching</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Regenecare® wound gel, in terms of reducing severity, redness, and appearance of rash</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Regenecare® wound gel as assessed by NCI CTCAE v3.0</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Dermatologic Complications</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>collagen/aloe vera/vitamin E/lidocaine topical hydrogel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of cancer&#xD;
&#xD;
          -  Starting treatment with cetuximab or other EGFR inhibitor (e.g., erlotinib&#xD;
             hydrochloride) on another clinical trial&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No known history of hypersensitivity to amine-type local anesthetics or to other&#xD;
             components of MPM Regenecare® wound gel&#xD;
&#xD;
          -  No other concurrent, serious skin disorders (i.e., scleroderma or psoriasis) that&#xD;
             would interfere with assessment of EGFR inhibitor-induced rash&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent topical facial creams or lotions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark F. Kozloff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ingalls Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ingalls Cancer Care Center at Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Ingalls Cancer Care Center at Ingalls</last_name>
      <phone>708-915-4673</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>dermatologic complications</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

